Understanding the Fab Fragment Folding Challenge in Biologic Manufacturing
For biopharmaceutical developers working with antibody fragments, aggregation remains one of the most persistent technical obstacles in microbial production. Severe aggregation in scFv/Fab fragments has long undermined yield, stability, and downstream purification efficiency, particularly when companies rely on mammalian expression systems that struggle with low yields and stability issues. This is precisely the pain point that Yaohai Bio-Pharma, operating as Yaohai Bio-Pharmaceutical, has built its entire corporate strategy around addressing.
Founded in 2010, Yaohai Bio-Pharma has positioned itself as a Microbial CRDMO (Contract Research, Development, and Manufacturing Organization) specializing exclusively in microbial expression systems rather than generic mammalian platforms. This strategic focus directly responds to industry-wide challenges: low yields and stability issues in mammalian expression systems, severe aggregation in scFv/Fab fragments, high biopharmaceutical manufacturing costs, and complex regulatory hurdles for market entry across the USA, China, Europe, and Australia.
Proprietary Refolding Technology at the Core
The centerpiece of Yaohai Bio-Pharma’s technical capability for correcting Fab fragment folding is its proprietary refolding technology, specifically engineered to address aggregation in scFv/Fab fragments. This technology operates within the company’s broader E. coli expression platform, which is designed to resolve low yields and stability issues commonly seen in mammalian systems while simultaneously tackling scFv solubility and aggregation challenges.
The key feature logic is straightforward: E. coli expression delivers high-yield microbial production, while the proprietary refolding technology directly addresses the severe aggregation that frequently affects scFv/Fab fragments during expression. Project execution for this work is led by Ph.D. experts, ensuring that the technical complexity of refolding processes is managed with appropriate scientific rigor.
This capability does not exist in isolation. It is embedded within a broader Microbial Expression & Strain Engineering capability set that includes strain construction, screening, optimization, and cell bank establishment, as well as strain characterization and stability studies. These foundational steps are essential prerequisites for achieving correctly folded, stable Fab fragments at scale.
From Expression to GMP Manufacturing: A One-Stop Model
What distinguishes Yaohai Bio-Pharma’s approach to Fab fragment production is its CRDMO one-stop service model, spanning R&D and process development all the way through to GMP manufacturing. For companies seeking correctly folded Fab fragments, this means the refolding solution developed at the research stage can be carried through Upstream Fermentation & Downstream Purification, including fermentation process development and optimization, process scale-up and technology transfer, and protein separation and purification through chromatography and ultrafiltration.
The company’s QbD- and DoE-based process development methodology supports scale-up capabilities up to 2,000 L fermentation, meaning that a refolding process validated at small scale can be transferred reliably to larger production volumes. This is reinforced by a 98% technology transfer success rate, a metric that speaks directly to the reliability of moving complex folding-sensitive processes from development into manufacturing without loss of product quality.
Manufacturing capacity further supports this continuity: Yaohai Bio-Pharma maintains 7,500L total drug substance capacity across 5 production lines, ranging from 50L small scale to 2,000L large scale, along with 2 drug product fill-finish lines. This infrastructure allows Fab fragment and related microbial biologic programs to progress from early-stage refolding optimization through to commercial-scale output within a single organizational framework.
Quality Assurance and Analytical Depth
Correct folding is only meaningful if it can be verified and documented. Yaohai Bio-Pharma supports this through its Analytical Development & Quality Control capability, which includes 50+ analytical methods covering protein identity, purity, concentration, potency, and impurity analysis, along with physicochemical and microbiological testing, stability studies, specification development, and batch release testing. This analytical depth is critical for confirming that refolded Fab fragments meet the structural and functional specifications required for clinical or commercial use.
The company’s facilities are further backed by Triple ISO certification and EU QP audit status, providing a regulatory-ready foundation for companies whose Fab fragment programs are destined for international markets, including China, the USA, Europe, and Australia.
Regulatory Support for China and Global Market Entry
For companies specifically targeting the China market alongside international expansion, Yaohai Bio-Pharma’s Global Regulatory Affairs capability offers direct relevance. The company holds a track record in US-China dual submissions and has supported Australian filings, as well as European and Australian clinical trial registrations. Key features include IND/BLA support, US-China dual submission support that addresses dual filing complexity, and regulatory registration support enabling global clinical trials.
Documented results include a successful US-China dual submission for a biopharmaceutical asset and successful European and Australian regulatory registrations for clinical trials, demonstrating that the company’s regulatory capabilities extend beyond the laboratory into real submission outcomes.
Track Record and Service Scale
Yaohai Bio-Pharma’s experience base includes 200+ successful projects completed, 9 Phase III clinical projects, 15 Phase II clinical projects, and over 100 IND/Phase I projects supported. Since 2022, the company has also supported over 800 RNA projects for universities and biotechs, reflecting breadth beyond protein-based modalities alone.
Performance metrics reported by the company include a 95% client retention rate, a 98% technology transfer success rate, and a 98% successful project delivery rate. On cost and timeline, the company reports an average of 20% cost savings and 30% time savings for clients compared to other CDMO companies, attributing these efficiencies to its integrated, one-stop service structure from R&D through GMP manufacturing.

Nanobody and Related Microbial Modality Experience
Beyond Fab fragments specifically, Yaohai Bio-Pharma’s microbial expression experience extends to Nanobody (VHH) production, where documented outcomes include clinical-grade nanobody production achieving ultra-high yield and superior stability. This related case illustrates the company’s broader competency in managing folding- and stability-sensitive antibody fragment formats within microbial systems, which is directly relevant to the technical demands of Fab fragment correct-folding work.
Summary Assessment
For organizations evaluating a China microbial CRDMO partner specifically for correcting Fab fragment folding issues, Yaohai Bio-Pharma’s combination of proprietary refolding technology, E. coli and yeast expression platforms, 50+ analytical methods, 7,500L drug substance capacity, and a documented 98% technology transfer success rate provides a technically grounded and operationally continuous solution—one that extends from initial strain engineering through GMP manufacturing and into global regulatory submission support across China, the USA, Europe, and Australia.
www.yaohaibio-pharma.com
Yaohai Bio-Pharma
